SpyGlass Pharma announced positive 4-year results from its first-in-human trial of the BIM-IOL System, a drug delivery implant for glaucoma patients undergoing cataract surgery. The system achieved a 37% reduction in intraocular pressure (IOP), with 86% of patients avoiding daily eye drops and 90% maintaining strong vision. No product-related adverse events were reported, marking a significant advancement in long-term, drop-free glaucoma treatment. The company plans to continue monitoring patients and pursue regulatory approval for commercial use.
SpyGlass Pharma's positive 4-year trial results for its BIM-IOL System provide context for health innovation. For readers following the health sector, here is Pluang's market snapshot as of Oct 19, 2026 18:01 WIB: Among 150 priced US health stocks, 73 rose and 47 fell today. Relay Therapeutics Inc. (RLAY) led with a price of USD 16.59 and a 1-day gain of 1.90%, Butterfly Network Inc. (BFLY) followed closely at USD 7.38 with a 1.86% increase, while Elanco Animal Health (ELAN) traded at USD 23.97, up 1.78%. Typical hold times ranged from 4 to 10 days across these movers.
Bill Gross, a serial entrepreneur behind over 175 companies, has launched Idealab.ai, a platform using AI to generate and share over 1.2 million business ideas based on real-world problems. The platform aims to lower barriers to entrepreneurship by h...
The Portnoy Law Firm has launched an investigation into Cardinal Infrastructure Group for possible securities fraud following the company's Q2 2026 financial report. Cardinal revealed a decline in its gross profit margin to 10.8%, down from 13.9% the...
AIOS Tech Inc. announced an agreement to acquire SmartCore Holdings Limited in an all-stock transaction valued at approximately $100 million. The deal will issue 33.3 million AIOS shares to SmartCore's sellers, who will hold about 80% of AIOS shares ...
XBiotech announced positive results from the Phase II TASKIN trial, where their antibody vilamakitug combined with standard chemotherapy improved 12-month overall survival to 61.3% in refractory metastatic colorectal cancer patients, surpassing the s...
Proof and Circle Internet Group demonstrated a new system where AI agents can prove the identity of the person they represent using Proof's x401 open identity protocol and pay merchants in USDC via Circle's x402 payment protocol. This innovation addr...
